2021-01-27
Citrine Medicine Announces Strategic Partnership to bring Alkindi® to China for Use in Pediatric Congenital Adrenal Hyperplasia (CAH)
Company Profile
Citrine Medicine is a therapeutics platform company focused on the Greater China market that was co-founded by Eight Roads Ventures, F-Prime Capital and Vivo Capital. We are dedicated to improving the lives of rare disease patients by making diagnosis and essential treatments available and accessible for those who need them.
Building The First Rare Disease Ecosystem In China.
Enabling Extraordinary People To Live More Ordinary Lives.
Wakix®
WAKIX® (pitolisant) is a narcolepsy treatment that Citrine has in-licensed from the French biotech company, Bioprojet, for use in China. Pitolisant is a selective histamine H3-receptor antagonist/inverse agonist
Press Releases
-
-
2021-01-08Citrine Medicine to Participate at Three Upcoming Biotech Industry Conferences -
2020-10-28Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix® (pitolisant) -
2020-10-28Chinese rare disease player inks first deal around narcolepsy drug Wakix after grabbing $80M to build an ecosystem